← Back to Blog

What Paul Conyngham Got Right (and What Most People Miss) About Personalized Cancer Treatment

When Paul Conyngham's story went viral in March 2026, most headlines focused on the AI angle — a tech entrepreneur using ChatGPT to cure his dog's cancer. But that framing misses the most important part of the story.

AI was the tool, not the breakthrough

ChatGPT didn't design the vaccine. It helped Conyngham navigate the research landscape and identify the right approach. The real breakthrough was the process: sequencing the tumor, comparing it against a healthy baseline genome, identifying neoantigens, predicting protein structures, and designing an mRNA construct. This workflow existed before ChatGPT — AI just made it accessible to a non-specialist.

The data was the breakthrough

The critical enabler was having both the tumor genome AND the healthy baseline genome. Without both, you can't compute the delta — the specific mutations driving the cancer. You can't identify neoantigens. You can't design a vaccine. The data made everything else possible.

The time factor most people miss

Conyngham had to get Rosie's healthy genome sequenced from scratch alongside her tumor genome. That sequencing process took weeks. For a dog with months to live, those weeks were a significant portion of her remaining life. For a human with aggressive cancer, the same delay could be the difference between treatment starting in time and starting too late.

The lesson for all of us

The story isn't about AI. It's about preparedness. If Rosie's genome had been pre-stored, the treatment timeline would have compressed dramatically. The healthy baseline would have been a database lookup — seconds instead of weeks. ReadyGenome exists to give you that advantage: your genome, already sequenced, already stored, ready the moment precision medicine needs it.

Related: How One Man Used AI to Save His Dog · Cancer Preparedness and Your Genome · View Pricing

Ready to secure your genome?

Join the Waitlist